somapacitan (Sogroya) Report issue

Small molecule Orphan Drug FDA Approved FDA
AACT ChEMBL PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: C=C(CCCCCCCCCCCCCCCc1nnn[nH]1)NS(=O)(=O)CCCC(=O)NCCOCCOCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)NCCOCCOCC(=O)N[C@@H](CCCCNC(=O)CSC[C@H](N)C(=O)O)C(N)=O)C(=O)O)C(=O)O
  • InChIKey: NAKSIOUBFDBTSW-ITMZJIMRSA-N
  • Mol. Mass: 1308.59
  • ALogP: Missing data
  • ChEMBL Molecule:
    somapacitan  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Alternative names

nn-8640 | nnc0195-0092 | somapacitan

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (1)


 

Dwarfism, Pituitary (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Dwarfism, Pituitary ()

Growth and Development (Phase 2)

Growth Hormone (Phase 3)

Healthy Volunteers (Phase 1)

Noonan Syndrome (Phase 3)

Turner Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 16
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue